Mounjaro vs Ozempic
Side-by-side cost comparison based on Medicare Part D data
Mounjaro
Tirzepatide
Manufactured by Eli Lilly
Ozempic
Semaglutide
Manufactured by Novo Nordisk
Mounjaro costs 2% less per claim than Ozempic ($673.00 vs $685.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Mounjaro | Ozempic |
|---|---|---|
| Avg Cost Per Claim | $673.00 | $685.00 |
| Total Medicare Spending | $2.5B | $5.0B |
| Total Beneficiaries | 524,000 | 1,180,000 |
| Total Claims | 3,680,000 | 7,240,000 |
| Annual Cost/Patient | $4,729.00 | $4,200.00 |
| Year-over-Year Change | +312.4% | +72.5% |
| Generic Available | No | No |
| Patent Expiration | May 13, 2036 | Sep 20, 2031 |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Condition | Diabetes | Diabetes |
| Generic Name | Tirzepatide | Semaglutide |
Mounjaro vs Ozempic: What the Data Shows
Mounjaro (Tirzepatide) and Ozempic (Semaglutide) are both used to treat diabetes. Based on Medicare Part D data, Mounjaro costs $673.00 per claim, which is 2% less than Ozempic at $685.00 per claim.
Medicare spent $2.5B on Mounjaro and $5.0B on Ozempic. In terms of patient reach, Ozempic serves more beneficiaries (1,180,000 vs 524,000).
Year-over-year spending changed +312.4% for Mounjaro and +72.5% for Ozempic. Mounjaro saw significant spending growth, suggesting increased utilization or price increases. Ozempic saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Mounjaro patent expires May 13, 2036. Ozempic patent expires Sep 20, 2031.
Frequently Asked Questions
Mounjaro is cheaper at $673.00 per claim, compared to $685.00 for Ozempic. That makes Mounjaro about 2% less expensive per claim based on Medicare Part D data.
Yes, both Mounjaro and Ozempic are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Mounjaro patent expires May 13, 2036. Ozempic patent expires Sep 20, 2031.
Medicare Part D spent $2.5B on Mounjaro covering 524,000 beneficiaries, and $5.0B on Ozempic covering 1,180,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.